Skip to main content
. 2014 Mar 4;44(5):1433–1442. doi: 10.3892/ijo.2014.2319

Figure 2.

Figure 2.

Figure 2.

O-glycosylation inhibitor, benzyl-GalNAc (BZ) treatment resulted in the enhancement of PNA and VVA lectin reactivity suggesting the inhibition of elongation of O-glycosylation (PNA, *P<0.05; VVA, **P<0.005; NS, not significant) (A). ConA and L-PHA lectin binding activity which is related to N-glycans was not dramatically changed. Treatment of BZ did not show alteration of cell adhesive capacity to human recombinant galectin-1 (NS, not significant; et, ethanol control; BZ, benzyl-GalNAc) (B). Representative results from two independent experiments in triplicate are shown.